Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA2001YUM" target="_blank" >RIV/61988987:17110/19:A2001YUM - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/19:E0107809
Result on the web
<a href="https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1480766?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1480766?needAccess=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2018.1480766" target="_blank" >10.1080/10428194.2018.1480766</a>
Alternative languages
Result language
angličtina
Original language name
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases
Original language description
A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8–30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53–222), with 5-year OS rate of 77% (95% CI: 61.0–87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia and Lymphoma
ISSN
1042-8194
e-ISSN
1029-2403
Volume of the periodical
60
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
471-476
UT code for WoS article
000463555600025
EID of the result in the Scopus database
2-s2.0-85050555358